Multi-target therapeutics: when the whole is greater than the sum of the parts

Drug Discovery Today

Volumn 12, Issue 1-2, 2007, Pages 34-42

  Zimmermann, Grant R ^a   Lehár, Joseph ^a,b   Keith, Curtis T ^a  

^a Department of Preclinical Development and Formulations   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMLODIPINE PLUS ATORVASTATIN; AMLODIPINE PLUS BENAZEPRIL; AMOXICILLIN PLUS CLAVULANIC ACID; BEVACIZUMAB; CANERTINIB; CETUXIMAB; COTRIMOXAZOLE; CYCLOSPORIN A; DASATINIB; DULOXETINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EZETIMIBE PLUS SIMVASTATIN; FLUOROURACIL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FOLINIC ACID; GLIBENCLAMIDE PLUS METFORMIN; IRINOTECAN; LAMIVUDINE PLUS ZIDOVUDINE; LAPATINIB; LOPINAVIR PLUS RITONAVIR; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; OXALIPLATIN; REBETRON; SORAFENIB; STEROID; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG;

ASTHMA; BACTERIAL INFECTION; BREAST CANCER; CANCER; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DEPRESSION; DISEASE MODEL; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GLYCEMIC CONTROL; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; IN VITRO STUDY; ISCHEMIC HEART DISEASE; MOLECULAR DYNAMICS; MOLECULAR PROBE; MOLECULAR RECOGNITION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; VIRUS INFECTION;

DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG THERAPY; HUMANS; MODELS, BIOLOGICAL;

EID: 33845762340     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.11.008     Document Type: Review

References (43)

1. Sams-Dodd F. Target-based drug discovery: is something wrong?. Drug Discov. Today 10 (2005) 139-147
2. Hartman IV J.L., et al. Principles for the buffering of genetic variation. Science 291 (2001) 1001-1004
3. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
4. Keith C.T., et al. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4 (2005) 71-78
5. Borisy A.A., et al. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7977-7982
6. Butcher E.C. Can cell systems biology rescue drug discovery?. Nat. Rev. Drug Discov. 4 (2005) 461-467
7. Fishman M.C., and Porter J.A. Pharmaceuticals: a new grammar for drug discovery. Nature 437 (2005) 491-493
8. Baylin S.B., and Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 6 (2006) 107-116
9. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5 (2006) 37-50
10. Tobert J.A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. 2 (2003) 517-526
11. Paolini G.V., et al. Global mapping of pharmacological space. Nat. Biotechnol. 24 (2006) 805-815
12. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 (2002) 727-730
13. Ideker T., et al. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. 2 (2001) 343-372
14. Mencher S.K., and Wang L.G. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin. Pharmacol. 5 (2005) 3
15. Renan M.J. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinog. 7 (1993) 139-146
16. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
17. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
18. Kubinyi H. Drug research: myths, hype and reality. Nat. Rev. Drug Discov. 2 (2003) 665-668
19. Johnston S.R. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin. Cancer Res. 11 (2005) 889-899
20. Dancey J.E., and Chen H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 5 (2006) 649-659
21. Britten C.D. Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol. Cancer Ther. 3 (2004) 1335-1342
22. Hynes N.E., and Lane H.A. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
23. Cheng A.Y., and Fantus I.G. Oral antihyperglycemic therapy for type 2 diabetes mellitus. J. Canadian Medical Association 172 (2005) 213-226
24. Zon L.I., and Peterson R.T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4 (2005) 35-44
25. Hartwell L.H., et al. Integrating genetic approaches into the discovery of anticancer drugs. Science 278 (1997) 1064-1068
26. MacKeigan J.P., et al. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol. 7 (2005) 591-600
27. Kawada M., et al. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res. 66 (2006) 4419-4425
28. Kaelin Jr. W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5 (2005) 689-698
29. Rottmann S., et al. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3β/FBW7 loss of function. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15195-15200
30. Bryant H.E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
31. Yeh P., et al. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 38 (2006) 489-494
32. Cheng Y., and Church G.M. Biclustering of expression data. Proc. Int. Conf. Intell. Syst. Mol. Biol. 8 (2000) 93-103
33. Perlman Z.E., et al. Multidimensional drug profiling by automated microscopy. Science 306 (2004) 1194-1198
34. Segre D., et al. Modular epistasis in yeast metabolism. Nat. Genet. 37 (2005) 77-83
35. Morphy R., et al. From magic bullets to designed multiple ligands. Drug Discov. Today 9 (2004) 641-651
36. Rubinfeld B., et al. Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat. Biotechnol. 24 (2006) 205-209
37. Roses A.D. Pharmacogenetics and the practice of medicine. Nature 405 (2000) 857-865
38. Greco W.R., et al. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47 (1995) 331-385
39. Bliss C.I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26 (1939) 585-615
40. Loewe S. Die quantitativen probleme der pharmakologie. Ergebn. Physiol. 27 (1928) 47-187
41. Chou T.C., and Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115 (1981) 207-216
42. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
43. Berenbaum M.C. The expected effect of a combination of agents: the general solution. J Theor. Biol. 114 (1985) 413-431